Announced
Completed
Synopsis
Zambon, an Italian pharmaceutical firm, completed the acquisition of Breath Therapeutics, which specializes in advanced and first-in-class inhalation therapies for severe respiratory diseases, from Sofinnova Partners, an European venture capital firm, for €500m ($557m). “Breath Therapeutics is a perfect symbol of our investment strategy: cutting-edge platform and products developed by brilliant entrepreneurs for a debilitating disease with no effective treatment. We had a clear vision in mind for a transatlantic operation with strong bases in Europe and in the US to maximize the commercial opportunity. We’ve achieved that vision and assembled a stellar management team by complementing the founders’ European skills with deep US clinical, regulatory and commercial expertise,” Graziano Seghezzi, Sofinnova Partners Managing Partner and Breath Therapeutics’ Board Member.
Principals
Show Details & Financials
Did you work on this deal?
Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.
By continuing, you agree to our Terms & Conditions and our Data Privacy Policy
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.